Ruxolitinib 20mg Tablet: Comprehensive Guide
Clinical Reference Standards: CDSCO (Central Drugs Standard Control Organisation), Indian Pharmacopoeia (IP) & WHO | Last Updated: September 2026
When to Call Your Doctor IMMEDIATELY
- Fever, chills, or persistent cough
- Unusual bleeding or bruising
- Yellowing of skin or eyes
- Confusion, memory loss, or difficulty walking
- Swelling of face, lips, or throat
- Severe abdominal pain
- Decreased urine output
If experiencing severe symptoms, call emergency services immediately.
What is jakavi 20mg tablet used for?
Ruxolitinib is a JAK1/JAK2 inhibitor used to treat myelofibrosis, polycythemia vera, and graft-versus-host disease. It works by blocking enzymes that cause excessive blood cell production and inflammation. It is taken orally, usually twice daily, and requires regular blood tests.
- Generic Name: Ruxolitinib (20mg)
- Manufacturer: Novartis India Ltd
- Form: Allopathy
- Pregnancy Category: Consult doctor
- Prescription Required: Yes
🇮🇳 jakavi 20mg tablet के बारे में (Hindi Summary)
उपयोग: यह दवा रुक्सोलिटिनिब नामक सक्रिय तत्व से बनी है, जो जैनस काइनेज (JAK) इनहिबिटर वर्ग की दवा है। इसका उपयोग मुख्य रूप से मायलोफाइब्रोसिस (अस्थि मज्जा में रेशेदार ऊतक का बढ़ना), पॉलीसाइथीमिया वेरा (रक्त में लाल रक्त कोशिकाओं की अधिकता), और ग्राफ्ट-वर्सेस-होस्ट डिजीज (अंग प्रत्यारोपण के बाद होने वाली प्रतिक्रिया) के इलाज के लिए किया जाता है। यह दवा प्लीहा (तिल्ली) के आकार को कम करने, थकान, रात में पसीना, खुजली और हड्डियों के दर्द जैसे लक्षणों को कम करने में मदद करती है। यह मौखिक रूप से ली जाती है और डॉक्टर की सलाह के अनुसार ही लेनी चाहिए।
साइड इफेक्ट्स: आम दुष्प्रभावों में सिरदर्द, चक्कर आना, थकान, और रक्त कोशिकाओं की कमी (एनीमिया, थ्रोम्बोसाइटोपेनिया) शामिल हैं। गंभीर दुष्प्रभावों में गंभीर संक्रमण, प्रगतिशील मल्टीफोकल ल्यूकोएन्सेफैलोपैथी (PML), और लिम्फोमा का खतरा बढ़ जाता है। यदि आपको बुखार, ठंड लगना, खांसी, या कोई असामान्य लक्षण दिखे तो तुरंत डॉक्टर से संपर्क करें।
सुरक्षा सलाह: यह दवा आपकी प्रतिरक्षा प्रणाली को कमजोर कर सकती है, इसलिए संक्रमण से बचने के लिए सावधानी बरतें। बार-बार हाथ धोएं और भीड़-भाड़ वाली जगहों से बचें। इस दवा को लेते समय लाइव वैक्सीन न लगवाएं। गर्भावस्था के दौरान इसका सेवन न करें, क्योंकि यह भ्रूण को नुकसान पहुंचा सकती है। अंगूर या अंगूर के जूस का सेवन न करें, क्योंकि इससे दवा का स्तर बढ़ सकता है। डॉक्टर की सलाह के बिना दवा बंद न करें।
💊 jakavi 20mg tablet Uses & Benefits
[{"condition":"Myelofibrosis","description":"Reduces spleen size, improves symptoms like fatigue, night sweats, and itching, and may improve survival in intermediate-2 or high-risk myelofibrosis.","evidence":"Well-established"},{"condition":"Polycythemia vera","description":"Used in patients who have had an inadequate response to or cannot tolerate hydroxyurea, to control blood counts and reduce spleen size.","evidence":"Well-established"},{"condition":"Acute graft-versus-host disease","description":"For steroid-refractory acute GVHD, it helps reduce inflammation and improve response rates.","evidence":"Well-established"},{"condition":"Chronic graft-versus-host disease","description":"May be used after failure of one or two lines of systemic therapy.","evidence":"Emerging"}]
Off-label uses: [{"condition":"Alopecia areata","description":"Topical or oral ruxolitinib has been studied for severe alopecia areata, but this is not an approved indication.","evidence":"Limited"},{"condition":"Atopic dermatitis","description":"Topical ruxolitinib is approved for atopic dermatitis, but oral use is off-label.","evidence":"Limited"},{"condition":"Vitiligo","description":"Topical ruxolitinib is approved for vitiligo, but oral use is off-label.","evidence":"Limited"}]
Primary treatment for: Myelofibrosis
Also treats: Polycythemia vera, Acute graft-versus-host disease, Chronic graft-versus-host disease
📋 Drug Information
| Generic Name(s) | Ruxolitinib (20mg) |
| Brand Name | jakavi 20mg tablet |
| Manufacturer | Novartis India Ltd |
| Packaging / Form | Varies by brand (Allopathy) |
| Therapeutic Class | ANTI NEOPLASTICS |
| Action Class | Tyrosine kinase inhibitors |
| Route of Administration | Oral |
| Storage | Store at room temperature between 20°C and 25°C (68°F to 77°F). Keep in the original container, tightly closed, away from moisture and heat. |
| Shelf Life | 24 months from the date of manufacture. |
| WHO Guideline | Not established from the available information. |
| ICMR Guideline | Not established from the available information. |
👨⚕️ Doctor's Practical Tips
Evidence-based practical advice from experienced clinicians
🔍 Is This Medicine Right for Your Symptom?
Educational reference. Always consult a doctor for diagnosis.
🔬 How This Medicine Works (Pharmacology)
Pharmacokinetics
How It Works
Ruxolitinib is a selective inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2). These enzymes are part of the JAK-STAT signaling pathway, which transmits signals from cytokines and growth factors to the cell nucleus, influencing gene expression. In myelofibrosis and polycythemia vera, mutations such as JAK2 V617F lead to constitutive activation of this pathway, causing excessive blood cell production and inflammation. By inhibiting JAK1 and JAK2, ruxolitinib reduces phosphorylation of STAT proteins, thereby decreasing inflammatory cytokine levels, reducing spleen size, and improving symptoms. It does not correct the underlying genetic mutation but manages the consequences of aberrant signaling.
Mechanism Steps
💡 How to Take jakavi 20mg tablet
Strength: 20 mg immediate-release tablet
Dosage Information
| Adult Dosage | The recommended starting dose for myelofibrosis is 20 mg orally twice daily for patients with platelet counts above 200,000/µL, and 15 mg twice daily for platelet counts between 100,000 and 200,000/µL. For polycythemia vera, the starting dose is 10 mg twice daily. For acute graft-versus-host disease, the dose is 5 mg twice daily. Dose must be individualized by a qualified clinician based on indication, blood counts, renal and hepatic function, and response to treatment. |
| Pediatric Dosage | Pediatric dosing is not established from available information. Consult a pediatrician. |
| Elderly Dosage | No specific dose adjustment is required for elderly patients, but they may be more susceptible to infections and blood count abnormalities. Monitor closely. |
| Renal Impairment | For patients with severe renal impairment (creatinine clearance less than 30 mL/min), reduce the dose by 50%. For moderate renal impairment, no adjustment is needed initially, but monitor closely. |
| Hepatic Impairment | For patients with severe hepatic impairment, reduce the dose by 50%. For mild to moderate hepatic impairment, no adjustment is needed initially, but monitor closely. |
| Maximum Daily Dose | The maximum recommended daily dose is 50 mg (25 mg twice daily) for myelofibrosis, but doses are individualized. |
Dosage Timeline
🍽️ Food Timing Guide
⏰ What to Do If You Miss a Dose
⚠️ Side Effects of jakavi 20mg tablet
✅ Common Side Effects
🚨 Serious Side Effects
⚠️ Rare Side Effects
Consult your doctor if you experience any unusual symptoms.
🔬 Drug Interactions
| Drug | Severity | Effect |
|---|---|---|
| Ketoconazole | Major | |
| Rifampin | Major | |
| Fluconazole | Moderate | |
| Warfarin | Moderate | |
| Live vaccines | Major |
🚨 Major Interactions
- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin)
- Strong CYP3A4 inducers (e.g., rifampin, carbamazepine)
- Live vaccines
⚡ Moderate Interactions
- Fluconazole
- CYP2C9 substrates (e.g., warfarin)
🍷 Alcohol Interaction
Alcohol may increase the risk of dizziness and liver problems. It is advisable to avoid or limit alcohol consumption while taking this medicine.
🔎 Check Your Other Medicines
Educational tool. Always confirm with your doctor or pharmacist.
🛡️ Safety & Warnings
🚫 Contraindications
["Hypersensitivity to ruxolitinib or any component of the formulation","Active serious infections","Severe hepatic impairment","Pregnancy and breastfeeding"]
⚠️ Warnings & Precautions
["May cause serious infections; monitor for signs and symptoms.","May cause thrombocytopenia, anemia, and neutropenia; monitor blood counts.","May cause progressive multifocal leukoencephalopathy (PML); monitor neurological symptoms.","May cause lymphoma; monitor for lymphadenopathy.","Avoid live vaccines during treatment.","May cause fetal harm; use effective contraception.","Do not stop abruptly; withdrawal symptoms may occur."]
🤱 Lactation Safety
It is not known whether ruxolitinib is excreted in human milk. Because of the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after the last dose.
💊 Overdose Management
There is no specific antidote for ruxolitinib overdose. Treatment should be symptomatic and supportive. Monitor blood counts and vital signs. In case of overdose, contact a poison control center or emergency room immediately.
⏰ Missed Dose
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time.
Additional Safety Advice
This medicine can weaken your immune system, so avoid close contact with people who have contagious infections. Wash your hands frequently and practice good hygiene. Do not receive live vaccines while taking this medicine. Inform your doctor immediately if you develop fever, chills, cough, or other signs of infection. Use effective contraception during treatment and for at least 2 weeks after the last dose, as this medicine can harm an unborn baby. Avoid grapefruit and grapefruit juice, as it may increase drug levels. Do not stop taking this medicine without consulting your doctor, as abrupt discontinuation can cause serious withdrawal symptoms.
👴 Special Considerations for Elderly
💡 For Patients Above 65
Elderly patients may be more susceptible to infections and blood count abnormalities. Close monitoring is recommended. No specific dose adjustment is required based solely on age.
🤰 Pregnancy Planning (TTC)
Ruxolitinib may cause fetal harm. Women of childbearing potential should use effective contraception during treatment and for at least 2 weeks after the last dose. If you are planning pregnancy, consult your doctor to discuss alternative treatments.
🏥 Post-Surgery Considerations
Ruxolitinib may increase the risk of bleeding and infection after surgery. Inform your surgeon that you are taking this medicine. Your doctor may recommend temporarily stopping the medicine before surgery.
🦷 Dental Procedures
Inform your dentist that you are taking ruxolitinib, as it may increase the risk of bleeding and infection. Your dentist may recommend precautions or consult with your doctor before proceeding.
💚 Lifestyle Tips for Better Results
🏋️ Exercise Considerations
Moderate exercise is encouraged, but avoid strenuous activities that may increase the risk of bleeding or injury, especially if platelet counts are low. Consult your doctor before starting any new exercise regimen.
🥗 Diet Recommendations
💼 Impact on Daily Work & Life
This medicine may cause dizziness and fatigue, which can affect your ability to drive or operate machinery. Avoid driving until you know how it affects you. It may also increase infection risk, so take precautions in workplace settings. Discuss with your employer about any necessary accommodations.
🛑 When to Stop This Medicine
Do not stop taking this medicine without consulting your doctor. If you experience severe side effects or if your disease progresses, your doctor may decide to discontinue or change the treatment. Abrupt withdrawal can cause serious symptoms like fever, chills, and spleen enlargement.
📅 Long-Term Use Effects
Long-term use of ruxolitinib may lead to persistent low blood counts, increased risk of infections, and potential development of lymphoma. Regular monitoring of blood counts, liver and kidney function, and signs of infection is essential. The benefits of treatment should be weighed against these risks, and therapy should be continued only if the benefits outweigh the risks.
🌿 Non-Medicine Approaches
These can complement medicine but do not replace prescribed treatment.
Another JAK2 inhibitor approved for myelofibrosis.
Evidence: Well-establishedJAK2 inhibitor for myelofibrosis with low platelets.
Evidence: Well-establishedPotentially curative option for eligible patients with myelofibrosis.
Evidence: Well-established💉 Vaccination Considerations
💉 If You're Getting Vaccinated
Live vaccines should not be administered during treatment with ruxolitinib. Inactivated vaccines may be less effective due to immune suppression. Consult your doctor before receiving any vaccine.
📦 Storage Guide
✅ DO
Store at room temperature (20-25°C)
❌ DON'T
Do not refrigerate
✅ DO
Keep in original container
❌ DON'T
Do not transfer to unmarked containers
✅ DO
Keep away from direct sunlight and moisture
❌ DON'T
Do not store in bathroom cabinet
✈️ Traveling with This Medicine
Carry this medicine in its original packaging with a copy of your prescription. Keep it in your carry-on luggage to avoid loss. Store at room temperature and protect from moisture. If traveling across time zones, adjust dosing times gradually in consultation with your doctor. Check customs regulations for controlled substances before traveling internationally.
💰 Cost Analysis & Savings
👥 Real Patient Stories
Educational, anonymized scenarios. Individual results may vary.
💬 Questions Patients Often Ask
A: Improvement in symptoms like spleen size and fatigue may be noticed within 2 to 4 weeks, but full benefits may take several months.
A: No, do not stop without consulting your doctor. Abrupt discontinuation can cause serious withdrawal symptoms.
A: Avoid grapefruit, live vaccines, and close contact with people who have infections. Use contraception if you are of childbearing age.
🤔 Common Patient Concerns
🛑 Myths vs. Facts
- Myth: Ruxolitinib is a cure for myelofibrosis.
Fact: Ruxolitinib manages symptoms and may improve survival but does not cure the disease. - Myth: Ruxolitinib weakens the immune system permanently.
Fact: Immune suppression is reversible after stopping the medicine, but infections can occur during treatment. - Myth: You can stop ruxolitinib abruptly if you feel better.
Fact: Abrupt discontinuation can cause serious withdrawal symptoms; always consult your doctor before stopping.